Ascend’s pipeline strategy focuses on a number of oncology and dermato-oncology settings. We believe that improved clinical outcomes can be achieved by preferentially targeting the tumor microenvironment, in particular key cellular subsets and molecular pathways that initiate and regulate the anti-cancer immune response and regulated cell death pathways.
Ascend applies a number of different technologies and approaches utilizing viral vectors, and affinity agents that can be conjugated to deliver biologicals and small molecule (immune modulators, kinase inhibitors or chemotherapeutics) payloads. We believe that applying a combination chemo-immunotherapeutic approach has the potential to materially improve therapeutic outcomes.
*RCD Regulated Cell Death; OC Ovarian Cancer; BCC Basal Cell Carcinoma; SCC Squamous Cell Carcinoma; BCL B Cell Lymphoma